Skip to main content

Table 1 Description of the sample and the prevalence of the diagnostic time of up to 3 and 12 months of symptons according to the independente variables in patients with rheumatoid arthritis of Blumenau, Santa Catarina, Brazil, 2014

From: Prevalence and factors associated with diagnosis of early rheumatoid arthritis in the south of Brazil

Variables Sample Diagnostic up to 3 months Diagnostic up to 12 months
N % Prevalence(%) CI 95% p Prevalence(%) CI 95% p
Total 296 100,0 27,7% (22,5–32,8)   64,8% (59,3-70,3)  
Sex (n = 296) 0,098a    0,708a
 Male 48 16,2 37,5 (23,2-51,7)   62,5 (48,2-76,7)  
 Female 248 83,8 25,8 (20,3–31,2)   65,3 (59,3-71,2)  
Age in years (n = 287) 0,227b    0,893b
 20–39 16 5,6 12,5 (5, 7–30,7)   62,5 (35,8-89,1)  
 40–59 146 50,9 26,7 (19,4–33,9)   65,7 (57,9-73,5)  
  ≥ 60 125 43,5 29,6 (21,5–37,7)   64,1 (55,4-72,5)  
Education in completed years (n = 284) 0,447b    0,093b
 0–4 106 37,3 27,4 (18,6–36,2)   70,5 (61,5-79,5)  
 5–8 76 26,7 21,1 (11,6–30,4)   64,4 (53,4-75,4)  
  > 9 102 35,9 32,1 (23,1- 41,1)   59,4 (49,9-68,9)  
Current monthly personal income in minimum wages (n = 248) 0,799b    0,493b
 Third tertile (higher) 82 33,1 28,5 (18,7–38,4)   59,5 (48,8-70,2)  
 Second tertile 82 33,1 25,6 (15,9–35,2)   65,8 (55,3-76,3)  
 First tertile (lower) 84 33,8 26,8 (17,1–36,6)   64,6 (54,1-75,2)  
Body mass index (Kg/m2) (n = 285) 0,012b    0,001b
  ≤ 24,9 110 38,6 36,3 (27,2-45,4)   75,4 (67,2-83,6)  
 25–29,9 113 39,7 24,7 (16,7–32,8)   61,9 (52,8-71,1)  
  ≥ 30 62 21,7 19,3 (9,2–29,3)   51,6 (38,8-64,4)  
Type of service in the last 12 months (n = 269) 0,166b    0,515b
 Public healthcare system 113 42,1 23,8 (15,9–31,8)   64,6 (55,7-73,4)  
 Supplementary healthcare system 84 31,2 27,3 (17,7–37,1)   65,4 (55,2-75,7)  
 Fee-for-service care 72 26,7 33,3 (22,3-44,3)   69,9 (58,6-80,2)  
Total number of consultations with a rheumatologist in the last 12 months (n = 281) 0,165b    0,069b
 0–1 42 15,0 33,3 (18,4-48,2)   69,1 (54,4-83,6)  
 2–3 126 44,9 23,0 (15,5 –30,4)   58,7 (50,0-67,4)  
  ≥ 4 113 40,1 30,9 (22,3–39,6)   69,9 (61,3-78,4)  
Disease time in months (n = 235) 0,193a    0,102a
 0–24 37 15,7 37,8 (21,4-54,2)   75,6 (61,1-90,1)  
  > 24 198 84,3 27,2 (21,1–33,5)   61,6 (54,7-68,4)  
Use of cs DMARD (n = 296) 0,396a    0,994a
 Yes 202 68,2 29,2 (22,8–35,5)   64,8 (58,2-71,4)  
 No 94 31,7 24,4 (15,6–33,3)   64,8 (55,1-74,7)  
Use of TNFi (ADA + ETA+IFX) (n = 288) 0,960a    0,592a
 Yes 75 26,1 28,0 (17,5–38,4)   61,3 (50,1-72,6)  
 No 213 73,9 27,6 (21,6–33,7)   64,7 (58,3-71,2)  
HAQ (n = 165) 0,904b    0,211b
 0–1 (mild) 65 39,4 24,6 (13,8–35,3)   55,3 (42,9-67,7)  
 1,1–2 (moderate) 59 35,7 32,2 (19,9-44,4)   69,4 (57,3-81,5)  
 2,1–3 (severe) 41 24,9 24,3 (10,6–38,1)   65,8 (50,7-81,0)  
Presence of radiological changes (erosions) in hands (n = 237) 0,814a    0,665a
 No 89 37,5 26,9 (17,5–36,3)   66,2 (56,2-76,3)  
 Yes 148 62,5 28,3 (21,1–35,7)   63,5 (55,6-71,3)  
Current professional situation (237) 0,325b    0,132b
 Working 77 32,5 23,3 (13,7 – 33,1)   59,7 (48,5 – 70,9)  
 Health insurance 29 12,2 24,1 (7,5 – 40,7)   55,1 (35,9 – 74,4)  
 Disability retirement 65 27,5 27,6 (16,5 – 38,8)   60,1 (47,7 – 77,2)  
 Retirement for time of service 66 27,8 30,3 (18,9 – 41,6)   72,2 (61,9 – 83,7)  
  1. csDMARD conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitors ADA adalimumab, ETA etanercept, IFX infliximab, HAQ health assessment questionnaire; CI 95%: confidence interval of 95%
  2. aChi-square test bWald’s linear trend test